SCHEMBL720091

SCHEMBL720091

CCOC(=O)CCN(C)C(=O)c1ccc(NC(c2oc3ccc(OCc4ccccc4)cc3c2C)C(C)C)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
NMT1 P30419 1/20 0.37
PKM P14618 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
ROCK1 Q13464 1/20 0.36
PPARG P37231 1/20 0.36
PPARD Q03181 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3399846 0.94 CASP3 (0.41) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL719948 0.90 CASP3 (0.41) CASP3SENP8SENP7SENP6MAPT
SCHEMBL719544 0.89 CASP3 (0.40) CASP3SENP8SENP7SENP6MAPT
SCHEMBL718680 0.88 KDM4E (0.34) MAPTL3MBTL1NPC1RAB9ATDP1
SCHEMBL718897 0.84 ABCG2 (0.35) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL718731 0.83 CASP3 (0.46) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL720636 0.83 CASP3 (0.44) CASP3SENP8SENP7SENP6MAPT
SCHEMBL718396 0.82 DGAT1 (0.37) NPC1RAB9A
SCHEMBL717422 0.81 DGAT1 (0.33) MAPTL3MBTL1
SCHEMBL719193 0.80 CASP3 (0.41) CASP3SENP8SENP7SENP6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP GABRA1 2147/4885GABRG2 2061/4885GABRB3 1398/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP GABRA1 2147/4885GABRG2 2061/4885GABRB3 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.